LeMaitre Vascular (LMAT) Worth a Look: Stock Jumps 19.5%
LeMaitre Vascular, Inc. LMAT was a big mover last session, as the company saw its shares jump above 19% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend for the company as the stock is now trading above the volatile price range of $27.94 to $31.99 in the past one-month time frame.
The company has seen one positive estimate revision in the past 30 days. Also, its Zacks Consensus Estimate moved higher over the same timeframe. Friday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
LeMaitre Vascular currently holds a Zacks Rank #2 (Buy).
LeMaitre Vascular, Inc. Price
LeMaitre Vascular, Inc. Price | LeMaitre Vascular, Inc. Quote
Another top-ranked stock in the Medical - Products industry is INSYS Therapeutics, Inc. INSY, which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is LMAT going up? Or down? Predict to see what others think: Up or Down
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
LeMaitre Vascular, Inc. (LMAT) : Free Stock Analysis Report
Insys Therapeutics, Inc. (INSY) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
